Press release from Companies
Publicerat: 2025-10-14 15:28:46
SensoDetect Aktiebolag (“SensoDetect” or the “Company”) has been informed that a shareholder’s holdings have crossed the thresholds for shares and votes that the Company, in accordance with Spotlight Stock Market’s regulations, is required to disclose.
SensoDetect has been notified that the Company’s largest shareholder, Thomas Holmgren, has passed away and that, prior to his death, he transferred 4.98 percent of his shareholding in the Company to his relatives.
Before the transfer, Thomas Holmgren’s holdings amounted to 15.18 percent of the capital and votes in the Company. After the transfer, the holdings in SensoDetect amount to 45,114,213 shares, corresponding to 10.20 percent of the capital and votes in the Company.
An updated and complete list of the Company’s ten largest shareholders will be published on the Company’s website.
“I personally extend my heartfelt gratitude for the support and contributions of Thomas Holmgren, whose wisdom, empathetic spirit, and entrepreneurial drive played a vital role in shaping me and, in that way, also SensoDetect. As a major shareholder and steadfast supporter, he believed deeply in the company’s mission and was instrumental in driving its growth and innovation. Though he is no longer with us, his influence and legacy will remain a guiding force in my work. I am profoundly thankful for all that he gave — his ideas, his integrity, and his belief in what we could achieve together. “, says Per-Anders Hedin, CEO of SensoDetect.
Informationen är sådan som SensoDetect AB är skyldigt att offentliggöra enligt lag (2007:528) om värdepappersmarknaden. Informationen lämnades, genom angiven kontaktpersons försorg, för offentliggörande 2025-10-14 15:28 CET.
For more information or partnership inquiries, please contact:
PA Hedin, CEO Sensodetect AB
+46 (0)46 15 79 04
pa.hedin@sensodetect.com
SensoDetect AB is a Med Tech AI company listed on the Spotlight Stock Market. The company was founded in Lund in 2005, based on more than 30 years of research in clinical psychoacoustics at the Department of Neuroscience at Lund University. Initially, the focus was on patients with schizophrenia, as auditory hallucinations are a common symptom of the disease. However, today, the company offers a variety of other services within the product areas of screening, diagnostics, medication, and health. The products are used in both private and public healthcare and schools, as a screening and complement to other observations in ADHD, schizophrenia, and autism assessments, in measuring the effects of medication, and in hearing screening. SensoDetect's unique and globally patented technology reduces the economic impact on healthcare and society while providing patients and their families with faster and more reliable results.
More info at https://www.sensodetect.com/
